Epigenetic regulation of cancer-associated genes in ovarian cancer

International Journal of Molecular Sciences

Volumn 12, Issue 2, 2011, Pages 983-1008

  Kwon, Mi Jeong ^a   Shin, Young Kee ^b  

^a Seoul National University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Cancer initiating cells; Chemoresistance; DNA methylation; Epigenetic derepression; Epigenetic therapy; Histone modification; miRNA; Ovarian cancer

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; BELINOSTAT; BIX 01294; CHETOCIN; CLAUDIN 3; CLAUDIN 4; GENE PRODUCT; HYDRALAZINE; LYSINE; MICRORNA; MICRORNA 125B; MICRORNA 214; MICRORNA 9; MOCETINOSTAT; PANOBINOSTAT; PCI 24781; PLATINUM DERIVATIVE; ROMIDEPSIN; SODIUM PHENYL BUTYRATE; SYNUCELIN GAMMA; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR GATA 6; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; ZEBULARINE;

ANGPTL2 GENE; ANTINEOPLASTIC ACTIVITY; ARID3B GENE; ARL11 GENE; BCL2 GENE; BMI1 GENE; BORIS GENE; BRAF GENE; BRCA2 GENE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CDH1 GENE; CDKN1A GENE; CDKN2A GENE; CELL ADHESION; CELL MIGRATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLDN3 GENE; CLDN4 GENE; COPY NUMBER VARIATION; CPG ISLAND; CTCF GENE; CTGF GENE; DAK1 GENE; DIRAS3 GENE; DLEC1 GENE; DNA METHYLATION; DNAJC15 GENE; DOWN REGULATION; EPIGENETICS; FBXO32 GENE; GATA4 GENE; GATA6 GENE; GENE DELETION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENE TARGETING; GENETIC ASSOCIATION; GENOME IMPRINTING; HISTONE MODIFICATION; HMGA2 GENE; HOXA10 GENE; HRAS GENE; HUMAN; ICAM1 GENE; MAL GENE; MCJ GENE; MLH1 GENE; MYELODYSPLASTIC SYNDROME; NFKB1 GENE; ONCOGENE; OPCML GENE; OVARY CANCER; PCSK6 GENE; PIK3CA GENE; POSTTRANSCRIPTIONAL GENE SILENCING; PROMOTER REGION; PTEN GENE; RASSF1 GENE; REVIEW; SNCG GENE; SNGG GENE; TP53 GENE; TRANSCRIPTION INITIATION; TUBB3 GENE; TUMOR SUPPRESSOR GENE; UPREGULATION; FEMALE; GENETIC EPIGENESIS; GENETICS; METABOLISM; OVARY TUMOR;

CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MICRORNAS; ONCOGENES; OVARIAN NEOPLASMS;

EID: 79952258618     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms12020983     Document Type: Review

References (138)

1. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60(5), 277-300.
2. Hennessy, B.T.; Coleman, R.L.; Markman, M. Ovarian cancer. Lancet 2009, 374(9698), 1371-1382.
3. Cho, K.R.; Shih, I.M. Ovarian cancer. Annu. Rev. Pathol. 2009, 4, 287-313.
4. Bast, R.C., Jr.; Hennessy, B.; Mills, G.B. The biology of ovarian cancer: new opportunities for translation. Nat. Rev. Cancer 2009, 9(6), 415-428.
5. Yap, T.A.; Carden, C.P.; Kaye, S.B. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat. Rev. Cancer 2009, 9(3), 167-181.
6. Feinberg, A.P.; Ohlsson, R.; Henikoff, S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 2006, 7(1), 21-33.
7. Sharma, S.; Kelly, T.K.; Jones, P.A. Epigenetics in cancer. Carcinogenesis 2010, 31(1), 27-36.
8. Balch, C.; Fang, F.; Matei, D.E.; Huang, T.H.; Nephew, K.P. Epigenetic Changes in Ovarian Cancer. Endocrinology 2009, 150, 4003-4011.
9. Vogelstein, B.; Kinzler, K.W. Cancer genes and the pathways they control. Nat. Med. 2004, 10(8), 789-799.
10. Croce, C.M. Oncogenes and cancer. N. Engl. J. Med. 2008, 358(5), 502-511.
11. Iacobuzio-Donahue, C.A. Epigenetic changes in cancer. Annu. Rev. Pathol. 2009, 4, 229-249.
12. Esteller, M. Epigenetics in cancer. N. Engl. J. Med. 2008, 358(11), 1148-1159.
13. Garzon, R.; Calin, G.A.; Croce, C.M. MicroRNAs in Cancer. Annu. Rev. Med. 2009, 60, 167-179.
14. Esteller, M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 2007, 8(4), 286-298.
15. Lamprecht, B.; Walter, K.; Kreher, S.; Kumar, R.; Hummel, M.; Lenze, D.; Kochert, K.; Bouhlel, M.A.; Richter, J.; Soler, E.; et al. Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nat. Med. 2010, 16(5), 571-579.
16. Turner, B.M. Cellular memory and the histone code. Cell 2002, 111(3), 285-291.
17. Turner, B.M. Reading signals on the nucleosome with a new nomenclature for modified histones. Nat. Struct. Mol. Biol. 2005, 12(2), 110-112.
18. Kouzarides, T. Chromatin modifications and their function. Cell 2007, 128(4), 693-705.
19. Lan, F.; Nottke, A.C.; Shi, Y. Mechanisms involved in the regulation of histone lysine demethylases. Curr. Opin. Cell Biol. 2008, 20(3), 316-325.
20. Bernstein, B.E.; Mikkelsen, T.S.; Xie, X.; Kamal, M.; Huebert, D.J.; Cuff, J.; Fry, B.; Meissner, A.; Wernig, M.; Plath, K.; Jaenisch, R.; Wagschal, A.; Feil, R.; Schreiber, S.L.; Lander, E.S. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006, 125(2), 315-326.
21. Golebiewska, A.; Atkinson, S.P.; Lako, M.; Armstrong, L. Epigenetic landscaping during hESC differentiation to neural cells. Stem Cells 2009, 27(6), 1298-1308.
22. Fuks, F. DNA methylation and histone modifications: teaming up to silence genes. Curr. Opin. Genet. Dev. 2005, 15(5), 490-495.
23. Simon, J.A.; Lange, C.A. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat. Res. 2008, 647(1-2), 21-29.
24. Vaissiere, T.; Sawan, C.; Herceg, Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat. Res. 2008, 659(1-2), 40-48.
25. Abbosh, P.H.; Montgomery, J.S.; Starkey, J.A.; Novotny, M.; Zuhowski, E.G.; Egorin, M.J.; Moseman, A.P.; Golas, A.; Brannon, K.M.; Balch, C.; Huang, T.H.; Nephew, K.P. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. Cancer Res. 2006, 66(11), 5582-5591.
26. Schlesinger, Y.; Straussman, R.; Keshet, I.; Farkash, S.; Hecht, M.; Zimmerman, J.; Eden, E.; Yakhini, Z.; Ben-Shushan, E.; Reubinoff, B.E.; Bergman, Y.; Simon, I.; Cedar, H. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet. 2007, 39(2), 232-236.
27. Vire, E.; Brenner, C.; Deplus, R.; Blanchon, L.; Fraga, M.; Didelot, C.; Morey, L.; Van Eynde, A.; Bernard, D.; Vanderwinden, J.M.; Bollen, M.; Esteller, M.; Di Croce, L.; de Launoit, Y.; Fuks, F. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006, 439(7078), 871-874.
28. Fuks, F.; Burgers, W.A.; Brehm, A.; Hughes-Davies, L.; Kouzarides, T. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat. Genet. 2000, 24(1), 88-91.
29. Rountree, M.R.; Bachman, K.E.; Baylin, S.B. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat. Genet. 2000, 25(3), 269-277.
30. Smallwood, A.; Esteve, P.O.; Pradhan, S.; Carey, M. Functional cooperation between HP1 and DNMT1 mediates gene silencing. Genes Dev. 2007, 21(10), 1169-1178.
31. van der Vlag, J.; Otte, A.P. Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat. Genet. 1999, 23(4), 474-478.
32. Fraga, M.F.; Ballestar, E.; Villar-Garea, A.; Boix-Chornet, M.; Espada, J.; Schotta, G.; Bonaldi, T.; Haydon, C.; Ropero, S.; Petrie, K.; et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 2005, 37(4), 391-400.
33. Ventura, A.; Jacks, T. MicroRNAs and cancer: short RNAs go a long way. Cell 2009, 136(4), 586-591.
34. Johnson, S.M.; Grosshans, H.; Shingara, J.; Byrom, M.; Jarvis, R.; Cheng, A.; Labourier, E.; Reinert, K.L.; Brown, D.; Slack, F.J. RAS is regulated by the let-7 microRNA family. Cell 2005, 120(5), 635-647.
35. Lee, Y.S.; Dutta, A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 2007, 21(9), 1025-1030.
36. Sampson, V.B.; Rong, N.H.; Han, J.; Yang, Q.; Aris, V.; Soteropoulos, P.; Petrelli, N.J.; Dunn, S.P.; Krueger, L.J. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res. 2007, 67(20), 9762-9770.
37. Cimmino, A.; Calin, G.A.; Fabbri, M.; Iorio, M.V.; Ferracin, M.; Shimizu, M.; Wojcik, S.E.; Aqeilan, R.I.; Zupo, S.; Dono, M.; Rassenti, L.; Alder, H.; Volinia, S.; Liu, C.G.; Kipps, T.J.; Negrini, M.; Croce, C.M. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. USA 2005, 102(39), 13944-13949.
38. Meng, F.; Henson, R.; Wehbe-Janek, H.; Ghoshal, K.; Jacob, S.T.; Patel, T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133(2), 647-658.
39. He, L.; He, X.; Lim, L.P.; de Stanchina, E.; Xuan, Z.; Liang, Y.; Xue, W.; Zender, L.; Magnus, J.; Ridzon, D.; Jackson, A.L.; Linsley, P.S.; Chen, C.; Lowe, S.W.; Cleary, M.A.; Hannon, G.J. A microRNA component of the p53 tumour suppressor network. Nature 2007, 447, 1130-1134.
40. Raver-Shapira, N.; Marciano, E.; Meiri, E.; Spector, Y.; Rosenfeld, N.; Moskovits, N.; Bentwich, Z.; Oren, M. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol. Cell 2007, 26(5), 731-743.
41. Chang, T.C.; Wentzel, E.A.; Kent, O.A.; Ramachandran, K.; Mullendore, M.; Lee, K.H.; Feldmann, G.; Yamakuchi, M.; Ferlito, M.; Lowenstein, C.J.; Arking, D.E.; Beer, M.A.; Maitra, A.; Mendell, J.T. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell 2007, 26(5), 745-752.
42. O'Donnell, K.A.; Wentzel, E.A.; Zeller, K.I.; Dang, C.V.; Mendell, J.T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435(7043), 839-843.
43. Chang, T.C.; Yu, D.; Lee, Y.S.; Wentzel, E.A.; Arking, D.E.; West, K.M.; Dang, C.V.; Thomas-Tikhonenko, A.; Mendell, J.T. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat. Genet. 2008, 40(1), 43-50.
44. Fabbri, M.; Garzon, R.; Cimmino, A.; Liu, Z.; Zanesi, N.; Callegari, E.; Liu, S.; Alder, H.; Costinean, S.; Fernandez-Cymering, C.; Volinia, S.; Guler, G.; Morrison, C.D.; Chan, K.K.; Marcucci, G.; Calin, G.A.; Huebner, K.; Croce, C.M. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. USA 2007, 104(40), 15805-15810.
45. Friedman, J.M.; Liang, G.; Liu, C.C.; Wolff, E.M.; Tsai, Y.C.; Ye, W.; Zhou, X.; Jones, P.A. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res. 2009, 69(6), 2623-2629.
46. Ma, L.; Teruya-Feldstein, J.; Weinberg, R.A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449(7163), 682-688.
47. Huang, Q.; Gumireddy, K.; Schrier, M.; le Sage, C.; Nagel, R.; Nair, S.; Egan, D.A.; Li, A.; Huang, G.; Klein-Szanto, A.J.; Gimotty, P.A.; Katsaros, D.; Coukos, G.; Zhang, L.; Pure, E.; Agami, R. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat. Cell Biol. 2008, 10(2), 202-210.
48. Schondorf, T.; Ebert, M.P.; Hoffmann, J.; Becker, M.; Moser, N.; Pur, S.; Gohring, U.J.; Weisshaar, M.P. Hypermethylation of the PTEN gene in ovarian cancer cell lines. Cancer Lett. 2004, 207(2), 215-220.
49. Yang, H.; Kong, W.; He, L.; Zhao, J.J.; O'Donnell, J.D.; Wang, J.; Wenham, R.M.; Coppola, D.; Kruk, P.A.; Nicosia, S.V.; Cheng, J.Q. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008, 68(2), 425-433.
50. Baldwin, R.L.; Nemeth, E.; Tran, H.; Shvartsman, H.; Cass, I.; Narod, S.; Karlan, B.Y. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res. 2000, 60(19), 5329-5333.
51. Feng, W.; Marquez, R.T.; Lu, Z.; Liu, J.; Lu, K.H.; Issa, J.P.; Fishman, D.M.; Yu, Y.; Bast, R.C. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 2008, 112(7), 1489-1502.
52. Chan, M.W.; Huang, Y.W.; Hartman-Frey, C.; Kuo, C.T.; Deatherage, D.; Qin, H.; Cheng, A.S.; Yan, P.S.; Davuluri, R.V.; Huang, T.H.; Nephew, K.P.; Lin, H.J. Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer. Neoplasia 2008, 10(9), 908-919.
53. Caslini, C.; Capo-chichi, C.D.; Roland, I.H.; Nicolas, E.; Yeung, A.T.; Xu, X.X. Histone modifications silence the GATA transcription factor genes in ovarian cancer. Oncogene 2006, 25(39), 5446-5461.
54. Iorio, M.V.; Visone, R.; Di Leva, G.; Donati, V.; Petrocca, F.; Casalini, P.; Taccioli, C.; Volinia, S.; Liu, C.G.; Alder, H.; Calin, G.A.; Menard, S.; Croce, C.M. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007, 67(18), 8699-6707.
55. Nam, E.J.; Yoon, H.; Kim, S.W.; Kim, H.; Kim, Y.T.; Kim, J.H.; Kim, J.W.; Kim, S. MicroRNA expression profiles in serous ovarian carcinoma. Clin. Cancer Res. 2008, 14(9), 2690-2695.
56. Bendoraite, A.; Knouf, E.C.; Garg, K.S.; Parkin, R.K.; Kroh, E.M.; O'Briant, K.C.; Ventura, A.P.; Godwin, A.K.; Karlan, B.Y.; Drescher, C.W.; Urban, N.; Knudsen, B.S.; Tewari, M. Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol. Oncol. 2010, 116(1), 117-125.
57. Sellar, G.C.; Watt, K.P.; Rabiasz, G.J.; Stronach, E.A.; Li, L.; Miller, E.P.; Massie, C.E.; Miller, J.; Contreras-Moreira, B.; Scott, D.; Brown, I.; Williams, A.R.; Bates, P.A.; Smyth, J.F.; Gabra, H. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat. Genet. 2003, 34(3), 337-343.
58. Lu, Z.; Luo, R. Z.; Peng, H.; Rosen, D.G.; Atkinson, E.N.; Warneke, C.; Huang, M.; Nishmoto, A.; Liu, J.; Liao, W.S.; Yu, Y.; Bast, R.C. Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer. Clin. Cancer Res. 2006, 12, (8), 2404-2413.
59. Tobias, E.S.; Hurlstone, A.F.; MacKenzie, E.; McFarlane, R.; Black, D.M. The TES gene at 7q31.1 is methylated in tumours and encodes a novel growth-suppressing LIM domain protein. Oncogene 2001, 20(22), 2844-2853.
60. Qiu, H.; Zhu, J.; Yuan, C.; Yan, S.; Yang, Q.; Kong, B. Frequent hypermethylation and loss of heterozygosity of the testis derived transcript gene in ovarian cancer. Cancer Sci. 2010, 101(5), 1255-1260.
61. Yanaihara, N.; Nishioka, M.; Kohno, T.; Otsuka, A.; Okamoto, A.; Ochiai, K.; Tanaka, T.; Yokota, J. Reduced expression of MYO18B, a candidate tumor-suppressor gene on chromosome arm 22q, in ovarian cancer. Int. J. Cancer 2004, 112(1), 150-154.
62. Ibanez de Caceres, I.; Battagli, C.; Esteller, M.; Herman, J.G.; Dulaimi, E.; Edelson, M.I.; Bergman, C.; Ehya, H.; Eisenberg, B.L.; Cairns, P. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res. 2004, 64(18), 6476-6481.
63. Kwong, J.; Lee, J.Y.; Wong, K.K.; Zhou, X.; Wong, D.T.; Lo, K.W.; Welch, W.R.; Berkowitz, R.S.; Mok, S.C. Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia 2006, 8(4), 268-278.
64. Petrocca, F.; Iliopoulos, D.; Qin, H. R.; Nicoloso, M. S.; Yendamuri, S.; Wojcik, S.E.; Shimizu, M.; Di Leva, G.; Vecchione, A.; Trapasso, F.; Godwin, A.K.; Negrini, M.; Calin, G.A.; Croce, C.M. Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer. Cancer Res. 2006, 66(21), 10287-10291.
65. Milde-Langosch, K.; Ocon, E.; Becker, G.; Loning, T. p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors. Int. J. Cancer 1998, 79(1), 61-65.
66. Katsaros, D.; Cho, W.; Singal, R.; Fracchioli, S.; Rigault De La Longrais, I.A.; Arisio, R.; Massobrio, M.; Smith, M.; Zheng, W.; Glass, J.; Yu, H. Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecol. Oncol. 2004, 94(3), 685-692.
67. Richon, V.M.; Sandhoff, T.W.; Rifkind, R.A.; Marks, P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA 2000, 97(18), 10014-10019.
68. Zhang, H.; Zhang, S.; Cui, J.; Zhang, A.; Shen, L.; Yu, H. Expression and promoter methylation status of mismatch repair gene hMLH1 and hMSH2 in epithelial ovarian cancer. Aust. N. Z. J. Obstet. Gynaecol. 2008, 48(5), 505-509.
69. Meng, C.F.; Dai, D.Q.; Guo, K.J. Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP. Ai Zheng 2008, 27(12), 1251-1255 (in Chinese).
70. Bai, T.; Tanaka, T.; Yukawa, K.; Maeda, M.; Umesaki, N. Reduced expression of death-associated protein kinase in human uterine and ovarian carcinoma cells. Oncol. Rep. 2004, 11(3), 661-665.
71. Yuecheng, Y.; Hongmei, L.; Xiaoyan, X. Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin. Exp. Metastasis 2006, 23(1), 65-74.
72. Chou, J.L.; Su, H.Y.; Chen, L.Y.; Liao, Y.P.; Hartman-Frey, C.; Lai, Y.H.; Yang, H.W.; Deatherage, D.E.; Kuo, C.T.; Huang, Y.W.; et al. Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Lab Invest. 2010, 90(3), 414-425.
73. Kikuchi, R.; Tsuda, H.; Kanai, Y.; Kasamatsu, T.; Sengoku, K.; Hirohashi, S.; Inazawa, J.; Imoto, I. Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer. Cancer Res. 2007, 67(15), 7095-7105.
74. Kikuchi, R.; Tsuda, H.; Kozaki, K.; Kanai, Y.; Kasamatsu, T.; Sengoku, K.; Hirohashi, S.; Inazawa, J.; Imoto, I. Frequent inactivation of a putative tumor suppressor, angiopoietin-like protein 2, in ovarian cancer. Cancer Res. 2008, 68(13), 5067-5075.
75. Arnold, J.M.; Cummings, M.; Purdie, D.; Chenevix-Trench, G. Reduced expression of intercellular adhesion molecule-1 in ovarian adenocarcinomas. Br. J. Cancer 2001, 85(9), 1351-1358.
76. Fu, Y.; Campbell, E.J.; Shepherd, T.G.; Nachtigal, M.W. Epigenetic regulation of proprotein convertase PACE4 gene expression in human ovarian cancer cells. Mol. Cancer Res. 2003, 1(8), 569-576.
77. Czekierdowski, A.; Czekierdowska, S.; Wielgos, M.; Smolen, A.; Kaminski, P.; Kotarski, J. The role of CpG islands hypomethylation and abnormal expression of neuronal protein synuclein-gamma (SNCG) in ovarian cancer. Neuro. Endocrinol. Lett. 2006, 27(3), 381-386.
78. Gupta, A.; Godwin, A.K.; Vanderveer, L.; Lu, A.; Liu, J. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res. 2003, 63(3), 664-673.
79. Woloszynska-Read, A.; James, S.R.; Link, P.A.; Yu, J.; Odunsi, K.; Karpf, A.R. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun. 2007, 7, 21.
80. Woloszynska-Read, A.; James, S.R.; Song, C.; Jin, B.; Odunsi, K.; Karpf, A.R. BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines. Cancer Immun. 2010, 10, 6.
81. Strathdee, G.; Davies, B.R.; Vass, J.K.; Siddiqui, N.; Brown, R. Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene. Carcinogenesis 2004, 25(5), 693-701.
82. Strathdee, G.; Vass, J. K.; Oien, K.A.; Siddiqui, N.; Curto-Garcia, J.; Brown, R. Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. Gynecol. Oncol. 2005, 97(3), 898-903.
83. Lee, P.S.; Teaberry, V.S.; Bland, A.E.; Huang, Z.; Whitaker, R.S.; Baba, T.; Fujii, S.; Secord, A.A.; Berchuck, A.; Murphy, S.K. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer. Int. J. Cancer 2010, 126(6), 1378-1389.
84. Cheng, W.; Jiang, Y.; Liu, C.; Shen, O.; Tang, W.; Wang, X. Identification of aberrant promoter hypomethylation of HOXA10 in ovarian cancer. J. Cancer Res. Clin. Oncol. 2010, 136(8), 1221-1227.
85. Izutsu, N.; Maesawa, C.; Shibazaki, M.; Oikawa, H.; Shoji, T.; Sugiyama, T.; Masuda, T. Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells. Int. J. Oncol. 2008, 32(6), 1227-1235.
86. Kwon, M.J.; Kim, S.S.; Choi, Y.L.; Jung, H.S.; Balch, C.; Kim, S.H.; Song, Y.S.; Marquez, V.E.; Nephew, K.P.; Shin, Y.K. Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications. Carcinogenesis 2010, 31(6), 974-983.
87. Zhang, L.; Volinia, S.; Bonome, T.; Calin, G.A.; Greshock, J.; Yang, N.; Liu, C.G.; Giannakakis, A.; Alexiou, P.; Hasegawa, K.; et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc. Natl. Acad. Sci. USA 2008, 105(19), 7004-7009.
88. Dahiya, N.; Sherman-Baust, C.A.; Wang, T.L.; Davidson, B.; Shih Ie, M.; Zhang, Y.; Wood, W., III; Becker, K.G.; Morin, P.J. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One 2008, 3(6), e2436.
89. Bhattacharya, R.; Nicoloso, M.; Arvizo, R.; Wang, E.; Cortez, A.; Rossi, S.; Calin, G.A.; Mukherjee, P. MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res. 2009, 69(23), 9090-9095.
90. Guo, L.M.; Pu, Y.; Han, Z.; Liu, T.; Li, Y.X.; Liu, M.; Li, X.; Tang, H. MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-kappaB1. FEBS J. 2009, 276(19), 5537-5546.
91. Guan, Y.; Yao, H.; Zheng, Z.; Qiu, G.; Sun, K. MiR-125b targets BCL3 and suppresses ovarian cancer proliferation. Int. J. Cancer 2010, doi: 10.1002/ijc.25575.
92. Cowden Dahl, K.D.; Dahl, R.; Kruichak, J.N.; Hudson, L.G. The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells. Neoplasia 2009, 11(11), 1208-1215.
93. Yang, N.; Kaur, S.; Volinia, S.; Greshock, J.; Lassus, H.; Hasegawa, K.; Liang, S.; Leminen, A.; Deng, S.; Smith, L.; Johnstone, C.N.; Chen, X.M.; Liu, C.G.; Huang, Q.; Katsaros, D.; Calin, G.A.; Weber, B.L.; Butzow, R.; Croce, C.M.; Coukos, G.; Zhang, L. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res. 2008, 68(24), 10307-10314.
94. Honda, H.; Pazin, M.J.; D'Souza, T.; Ji, H.; Morin, P.J. Regulation of the CLDN3 Gene in Ovarian Cancer Cells. Cancer Biol. Ther. 2007, 6(11), 1733-1742.
95. Litkouhi, B.; Kwong, J.; Lo, C.M.; Smedley, J.G., III; McClane, B.A.; Aponte, M.; Gao, Z.; Sarno, J.L.; Hinners, J.; Welch, W.R.; Berkowitz, R.S.; Mok, S.C.; Garner, E.I. Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin. Neoplasia 2007, 9(4), 304-314.
96. Honda, H.; Pazin, M.J.; Ji, H.; Wernyj, R.P.; Morin, P.J. Crucial roles of Sp1 and epigenetic modifications in the regulation of the CLDN4 promoter in ovarian cancer cells. J. Biol. Chem. 2006, 281(30), 21433-21444.
97. Clarke, M.F.; Dick, J.E.; Dirks, P.B.; Eaves, C.J.; Jamieson, C.H.; Jones, D.L.; Visvader, J.; Weissman, I.L.; Wahl, G.M. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006, 66(19), 9339-9344.
98. Bonnet, D.; Dick, J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3(7), 730-737.
99. O'Brien, C.A.; Kreso, A.; Jamieson, C.H. Cancer stem cells and self-renewal. Clin. Cancer Res. 2010, 16(12), 3113-3120.
100. Bapat, S.A.; Mali, A.M.; Koppikar, C.B.; Kurrey, N.K. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 2005, 65(8), 3025-3029.
101. Zhang, S.; Balch, C.; Chan, M.W.; Lai, H.C.; Matei, D.; Schilder, J.M.; Yan, P.S.; Huang, T.H.; Nephew, K.P. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008, 68(11), 4311-4320.
102. + cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 2010, 29(18), 2672-2680.
103. + ovarian cancer cells. Oncogene 2009, 28(2), 209-218.
104. Curley, M.D.; Therrien, V.A.; Cummings, C.L.; Sergent, P.A.; Koulouris, C.R.; Friel, A.M.; Roberts, D.J.; Seiden, M.V.; Scadden, D.T.; Rueda, B.R.; Foster, R. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 2009, 27(12), 2875-2883.
105. Alvero, A.B.; Chen, R.; Fu, H.H.; Montagna, M.; Schwartz, P.E.; Rutherford, T.; Silasi, D.A.; Steffensen, K.D.; Waldstrom, M.; Visintin, I.; Mor, G. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 2009, 8(1), 158-166.
106. Wei, X.; Dombkowski, D.; Meirelles, K.; Pieretti-Vanmarcke, R.; Szotek, P.P.; Chang, H.L.; Preffer, F.I.; Mueller, P.R.; Teixeira, J.; MacLaughlin, D.T.; Donahoe, P.K. Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics. Proc. Natl. Acad. Sci. USA 2010, 107(44), 18874-18879.
107. Landen, C.N., Jr.; Goodman, B.; Katre, A.A.; Steg, A.D.; Nick, A.M.; Stone, R.L.; Miller, L.D.; Mejia, P.V.; Jennings, N.B.; Gershenson, D.M.; Bast, R.C., Jr.; Coleman, R.L.; Lopez-Berestein, G.; Sood, A.K. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol. Cancer Ther. 2010, 9(12), 3186-3199.
108. Surani, M.A.; Hayashi, K.; Hajkova, P. Genetic and epigenetic regulators of pluripotency. Cell 2007, 128(4), 747-762.
109. Ohm, J.E.; McGarvey, K.M.; Yu, X.; Cheng, L.; Schuebel, K.E.; Cope, L.; Mohammad, H.P.; Chen, W.; Daniel, V.C.; Yu, W.; Berman, D.M.; Jenuwein, T.; Pruitt, K.; Sharkis, S.J.; Watkins, D.N.; Herman, J.G.; Baylin, S.B. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat. Genet. 2007, 39(2), 237-242.
110. DeSano, J.T.; Xu, L. MicroRNA regulation of cancer stem cells and therapeutic implications. AAPS J. 2009, 11(4), 682-692.
111. Gifford, G.; Paul, J.; Vasey, P.A.; Kaye, S.B.; Brown, R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin. Cancer Res. 2004, 10(13), 4420-4426.
112. Su, H.Y.; Lai, H.C.; Lin, Y.W.; Liu, C.Y.; Chen, C.K.; Chou, Y.C.; Lin, S.P.; Lin, W.C.; Lee, H.Y.; Yu, M.H. Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int. J. Cancer 2010, 127(3), 555-567.
113. Nicholson, L.J.; Smith, P.R.; Hiller, L.; Szlosarek, P.W.; Kimberley, C.; Sehouli, J.; Koensgen, D.; Mustea, A.; Schmid, P.; Crook, T. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. Int. J. Cancer 2009, 125(6), 1454-1463.
114. Li, M.; Balch, C.; Montgomery, J.S.; Jeong, M.; Chung, J.H.; Yan, P.; Huang, T.H.; Kim, S.; Nephew, K.P. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med. Genomics 2009, 2, 34.
115. Boren, T.; Xiong, Y.; Hakam, A.; Wenham, R.; Apte, S.; Chan, G.; Kamath, S.G.; Chen, D.T.; Dressman, H.; Lancaster, J.M. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol. Oncol. 2009, 113(2), 249-255.
116. Ellis, L.; Atadja, P.W.; Johnstone, R.W. Epigenetics in cancer: targeting chromatin modifications. Mol. Cancer Ther. 2009, 8(6), 1409-1420.
117. Gal-Yam, E.N.; Saito, Y.; Egger, G.; Jones, P.A. Cancer epigenetics: modifications, screening, and therapy. Annu. Rev. Med. 2008, 59, 267-280.
118. Szyf, M. Epigenetics, DNA methylation, and chromatin modifying drugs. Annu. Rev. Pharmacol. Toxicol. 2009, 49, 243-263.
119. Xu, W.S.; Parmigiani, R.B.; Marks, P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26(37), 5541-5552.
120. Tan, J.; Yang, X.; Zhuang, L.; Jiang, X.; Chen, W.; Lee, P.L.; Karuturi, R.K.; Tan, P.B.; Liu, E.T.; Yu, Q. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007, 21(9), 1050-1063.
121. Greiner, D.; Bonaldi, T.; Eskeland, R.; Roemer, E.; Imhof, A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat. Chem. Biol. 2005, 1(3), 143-145.
122. Kubicek, S.; O'Sullivan, R.J.; August, E.M.; Hickey, E.R.; Zhang, Q.; Teodoro, M.L.; Rea, S.; Mechtler, K.; Kowalski, J.A.; Homon, C.A.; Kelly, T.A.; Jenuwein, T. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol. Cell 2007, 25(3), 473-481.
123. Huang, Y.; Greene, E.; Murray Stewart, T.; Goodwin, A.C.; Baylin, S.B.; Woster, P.M.; Casero, R.A., Jr. Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc. Natl. Acad. Sci. USA 2007, 104(19), 8023-8028.
124. Huang, Y.; Stewart, T.M.; Wu, Y.; Baylin, S.B.; Marton, L.J.; Perkins, B.; Jones, R.J.; Woster, P.M.; Casero, R.A., Jr. Novel Oligoamine Analogues Inhibit Lysine-Specific Demethylase 1 and Induce Reexpression of Epigenetically Silenced Genes. Clin. Cancer Res. 2009, 15, 7217.
125. Cameron, E.E.; Bachman, K.E.; Myohanen, S.; Herman, J.G.; Baylin, S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 1999, 21(1), 103-107.
126. Issa, J.P. DNA methylation as a therapeutic target in cancer. Clin. Cancer Res. 2007, 13(6), 1634-1637.
127. Fiskus, W.; Buckley, K.; Rao, R.; Mandawat, A.; Yang, Y.; Joshi, R.; Wang, Y.; Balusu, R.; Chen, J.; Koul, S.; Joshi, A.; Upadhyay, S.; Atadja, P.; Bhalla, K.N. Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. Cancer Biol. Ther. 2009, 8(10), 939-950.
128. Yoo, C.B.; Jones, P.A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 2006, 5(1), 37-50.
129. Jones, P.A.; Baylin, S.B. The epigenomics of cancer. Cell 2007, 128(4), 683-692.
130. Gaudet, F.; Hodgson, J.G.; Eden, A.; Jackson-Grusby, L.; Dausman, J.; Gray, J.W.; Leonhardt, H.; Jaenisch, R. Induction of tumors in mice by genomic hypomethylation. Science 2003, 300(5618), 489-492.
131. Eden, A.; Gaudet, F.; Waghmare, A.; Jaenisch, R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003, 300(5618), 455.
132. Plumb, J.A.; Strathdee, G.; Sludden, J.; Kaye, S.B.; Brown, R. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 2000, 60(21), 6039-6044.
133. Qian, X.; LaRochelle, W.J.; Ara, G.; Wu, F.; Petersen, K.D.; Thougaard, A.; Sehested, M.; Lichenstein, H.S.; Jeffers, M. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol. Cancer Ther. 2006, 5(8), 2086-2095.
134. Lin, C.T.; Lai, H.C.; Lee, H.Y.; Lin, W.H.; Chang, C.C.; Chu, T.Y.; Lin, Y.W.; Lee, K.D.; Yu, M.H. Valproic acid resensitizes cisplatin-resistant ovarian cancer cells. Cancer Sci. 2008, 99(6), 1218-1226.
135. Steele, N.; Finn, P.; Brown, R.; Plumb, J.A. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br. J. Cancer 2009, 100(5), 758-763.
136. Asadollahi, R.; Hyde, C.A.; Zhong, X.Y. Epigenetics of ovarian cancer: from the lab to the clinic. Gynecol. Oncol. 2010, 118(1), 81-87.
137. Fu, S.; Hu, W.; Iyer, R.; Kavanagh, J.J.; Coleman, R.L.; Levenback, C.F.; Sood, A.K.; Wolf, J.K.; Gershenson, D.M.; Markman, M.; Hennessy, B.T.; Kurzrock, R.; Bast, R.C., Jr. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 2010, doi: 10.1002/cncr.25701.
138. Fang, F.; Balch, C.; Schilder, J.; Breen, T.; Zhang, S.; Shen, C.; Li, L.; Kulesavage, C.; Snyder, A.J.; Nephew, K.P.; Matei, D.E. A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer 2010, 116(17), 4043-4053.